Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F16%3A00092817" target="_blank" >RIV/00216224:14110/16:00092817 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/978-3-319-27601-4_42" target="_blank" >http://dx.doi.org/10.1007/978-3-319-27601-4_42</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/978-3-319-27601-4_42" target="_blank" >10.1007/978-3-319-27601-4_42</a>

Result language
angličtina
Original language name
Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Original language description
Most patients with recurrent or metastatic head and neck squamous cell cancers qualify for palliative treatment. The management of these patients includes supportive care only, mono- or multiagent chemotherapy, and more recently targeted therapies. While platinum-based combinations are superior to single-agent therapies in terms of response rate, they are more toxic and so far have not shown to lead to meaningful survival benefit. Attempts to improve on this by using other or additional cytotoxic drugs were unsuccessful in the last 30 years. It was therefore an urgent need to investigate the efficacy of novel anticancer therapies that specifically target the tumor cells in such patients. A recent randomized trial showed that adding cetuximab, an EGFR-directed monoclonal antibody, to a standard platinum-based chemotherapy regimen led to an important survival benefit.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)